Catherine Do - 29 Jan 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Reporting relationship: Director
Issuer ticker: DMAA
Reported as of: 29 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2025, 19:23:49 UTC
Prior SEC filing: 10 Jan 2025
Next SEC filing: 24 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Catherine Do

Key filing fact

Catherine Do filed Form 4 for Drugs Made In America Acquisition Corp. (DMAA) on 03 Feb 2025.

Key facts

This page summarizes Catherine Do's Form 4 filing for Drugs Made In America Acquisition Corp. (DMAA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Feb 2025, 19:23.

Change

Previous filing in this sequence was filed on 10 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAA transaction

Ordinary shares

Other

Transaction value
Shares: +100,000
Change %
Price
Shares after: 100,000
Date: 29 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As of the Transaction Date, the reporting person acquired 100,000 ordinary shares from Drugs Made In America Acquisition LLC, the Issuer's sponsor, for no consideration.